US & Europe Orphan Drug Market: 817 Orphan Designated Drug in Clinical Development Phase in US & Europe Says "US & Europe Orphan Drug Pipeline" Report by PNS Pharma

US & Europe will dominate the global orphan drug market in terms of market sales and new orphan drug development in future. US has 507 orphan designated drug in clinical development phase as compare to 310 orphan designated drugs in Europe as per recently published “US Orphan Drug Pipeline Analysis” & “Europe Orphan Drug Pipeline Analysis” research reports by PNS Pharma.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
More Than 800 Orphan Designated Drugs are Currently Under Development in US & Europe

Delhi (PRWEB) October 15, 2013

US & Europe will continue to dominate the global orphan drug market in terms of market sales and new orphan drug development in future. US has 507 orphan designated drug in clinical development phase as compare to 310 orphan designated drugs in Europe.

“US Orphan Drug Pipeline Analysis” & “Europe Orphan Drug Pipeline Analysis” research reports by PNS Pharma gives comprehensive insight on the various orphan designated drugs being developed for the treatment of rare disease in US & Europe. These two reports include comprehensive insight on all the orphan designated drugs being developed in various clinical phases in US & Europe. These two reports also enable pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the US & Europe Orphan Drug market based upon development process.

Following parameters for each drug profile in development phase are covered in “US Orphan Drug Pipeline Analysis” & “Europe Orphan Drug Pipeline Analysis” research report:

  • Drug Profile Overview
  • Alternate Names for Drug
  • Active Indication
  • Phase of Development
  • Mechanism of Action
  • Brand Name
  • Patent Information
  • Orphan Designation by Indication, Country & Organisation
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class
  • ATC Codes

US Orphan Drug Development Pipeline by Clinical Phase:

  • Research: 4
  • Preclinical: 54
  • Phase-I: 68
  • Phase-I/II: 62
  • Phase-II: 169
  • Phase-II/III: 15
  • Phase-III: 93
  • Preregistration: 28
  • Registration: 18
  • Marketed: 137

Europe Orphan Drug Development Pipeline by Clinical Phase:

  • Preclinical: 29
  • Phase-I: 25
  • Phase-I/II: 37
  • Phase-II: 100
  • Phase-II/III: 13
  • Phase-III: 79
  • Preregistration: 18
  • Registration: 9
  • Marketed: 100

Report Web Link: “US Orphan Drug Pipeline Analysis” & “Europe Orphan Drugs Pipeline Analysis”

For Report Sample Contact:

Rajesh Sharma
Sr. Analyst (Drug Pipeline)
+91-11-47067990

Recently Published Drug Pipeline Reports:

  • Global Cancer Vaccines Pipeline Analysis
  • Global HIV Infection Pipeline Analysis
  • Global Infertility Drug Pipeline Analysis
  • Global Oncolytic Virus Therapy Pipeline Analysis
  • Global DNA Vaccine Pipeline Analysis
  • Global RNAi Drug Pipeline Analysis
  • Global Cell Therapy Pipeline Analysis
  • Gene Therapy Drug Pipeline Analysis
  • Pancreatic Cancer Drug Pipeline Analysis
  • Hepatitis C Drug Pipeline Analysis
  • Malaria Disease Drug Pipeline Analysis
  • Ovarian Cancer Pipeline Analysis

Upcoming Drug Pipeline Reports:

  • Orphan Drugs for Cancer
  • Type 1 Diabetes Drug
  • Type 2 Diabetes Drug
  • Global Monoclonal Antibodies (mAb) Pipeline
  • Influenza A Virus Pipeline
  • Breast Cancer Drug Pipeline


Contact